There are 2789 resources available
1026TiP - A phase Ib/II, open-label, multicenter, dose-escalation and dose-expansion study of NKTR-255 plus cetuximab as a salvage regimen in patients with solid tumors
Presenter: Mehmet Altan
Session: ePoster Display
1027TiP - A phase Ib study of CM24 in combination with nivolumab in adults with advanced solid tumors, followed by a phase IIa study of CM24 in combination with nivolumab in NSCLC, and in combination with nivolumab and nab-paclitaxel in pancreatic cancer
Presenter: Erkut Borazanci
Session: ePoster Display
1028TiP - ARC-12: Phase I/Ib dose escalation and dose expansion study to evaluate the safety and tolerability of AB308 + zimberelimab (AB122) in advanced malignancies
Presenter: Justin Call
Session: ePoster Display
1053P - Tumour mutational burden (TMB) assessment using next generation sequencing (NGS) for the prediction of complete response (CR) to immunotherapy (IO) in metastatic melanoma
Presenter: Timothy Humphries
Session: ePoster Display
1119P - Genomic alterations of neuroendocrine carcinoma originated from female genital tract
Presenter: MeiYu Fang
Session: ePoster Display
1120P - The prognostic and predictive roles of Ki67 and functional imaging tests in patients (pts) with metastatic pheochromocytoma or paraganglioma (mPPGL) treated with chemotherapy
Presenter: Samara Pacheco
Session: ePoster Display
1056P - Survival of patients with advanced melanoma according to first-line treatment and key prognostic factors: Real-world data from GEM1801 study
Presenter: Ivan Marquez-Rodas
Session: ePoster Display
1057P - ROS1 mutation can serve- as a potential efficacious predictor of immunotherapy in melanoma patients
Presenter: Hucheng Liu
Session: ePoster Display
1058P - Treatment outcomes with unselected autologous tumor infiltrating lymphocytes (TILs) in patients (pts) with checkpoint inhibition–refractory advanced cutaneous melanoma
Presenter: Manon Pillai
Session: ePoster Display
1059P - 18F-FDG-PET/CT response assessment in patients with advanced melanoma treated with combination of low-dose ipilimumab and anti-PD1: A real-world experience
Presenter: Caio De Liz
Session: ePoster Display